# Envudeucitinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/envudeucitinib

> The next catalyst for envudeucitinib, sponsored by ALUMIS INC. (ALMS), is its trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for envudeucitinib?

The next catalyst for envudeucitinib, sponsored by ALUMIS INC. (ALMS), is its trial start, 1H 2027. Press release filed with the SEC (EX-99): "Alumis plans to initiate a Phase 2 biomarker trial for A-005, its central nervous system penetrant TYK2 inhibitor, in patients with Parkinson's disease, in the first half of 2027." [Calendar and source filings](https://sec-api.dev/pdufa/envudeucitinib)

Source: Press release filed with the SEC (EX-99), accession 0001847367-26-000016, https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-08-13. Cite: https://sec-api.dev/pdufa/envudeucitinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | envudeucitinib |
| Codes | ESK-001 |
| Sponsor | ALUMIS INC. (ALMS) https://sec-api.dev/companies/alms/catalysts |
| Indications | systemic lupus erythematosus, with topline data, with moderate-to-severe plaque psoriasis, the timing of alumis' topline readout, [parkinson's disease](https://sec-api.dev/indications/parkinson-s-disease), moderate-to-severe plaque psoriasis, the timing, SLE, [Plaque Psoriasis](https://sec-api.dev/indications/plaque-psoriasis) |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### Jul 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-19, last confirmed 2025-05-14.
- SEC Form 10-Q (accession 0001847367-25-000028): "In addition to our Phase 3 program in PsO, which we announced in July 2024 had commenced patient dosing, we have initiated a Phase 2b trial of ESK-001 in SLE." https://www.sec.gov/Archives/edgar/data/1847367/000184736725000028/alms-20250331x10q.htm
- SEC Form 10-K (accession 0001847367-25-000012): "In addition to our Phase 3 program in PsO, which we announced in July 2024 had commenced patient dosing, we have initiated the first of potentially two pivotal Phase 2 trials of ESK-001 in SLE." https://www.sec.gov/Archives/edgar/data/1847367/000184736725000012/tmb-20241231x10k.htm

### 2H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-03-19, last confirmed 2025-03-19.
- Press release filed with the SEC (EX-99) (accession 0001847367-25-000010): "We also plan to initiate a Phase 2 trial of A-005 in multiple sclerosis in the second half of 2025 and expect data from ESK-001's Phase 2b clinical trial in systemic lupus erythematosus in 2026." https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-25-000010): "Data support planned initiation of Phase 2 clinical trial in multiple sclerosis in 2H 2025." https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm

### September 19, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06586112 (A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Alumis Inc." https://clinicaltrials.gov/study/NCT06586112

### September 23, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06588738 (A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor Alumis Inc." https://clinicaltrials.gov/study/NCT06588738

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2024-11-13, last confirmed 2026-01-08.
- Press release filed with the SEC (EX-99) (accession 0001847367-25-000048): "Our teams have been working diligently, and we are eagerly anticipating key milestones ahead - with topline Phase 3 ONWARD data for envudeucitinib (envu) in moderate-to-severe plaque psoriasis (PsO) expected to be announced early in the first quarter of 2026, followed by topline Phase 2b LUMUS data in systemic lupus erythematosus (SLE) in the third quarter," said Martin Babler, President and Chief Executive Officer of Alumis." https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-25-000039): "-Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026-" https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-25-000010): ""The next 12-18 months will bring major milestones for Alumis, with topline data from the pivotal Phase 3 program for ESK-001 in moderate-to-severe plaque psoriasis expected in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm
- SEC prospectus (424B) (accession 0001104659-26-002203): "With the favorable results in our Phase 2 clinical trial in PsO, we have initiated our Phase 3 ONWARD clinical program, which consists of two parallel Phase 3 clinical trials of ESK-001 in this indication and for which we expect to report topline results early in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000110465926002203/tm2534587-3_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-001410): "With the favorable results in our Phase 2 clinical trial in PsO, we have initiated our Phase 3 ONWARD clinical program, which consists of two parallel Phase 3 clinical trials of ESK-001 in this indication and for which we expect to report topline results early in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000110465926001410/tm2534587-1_424b5.htm
- SEC Form 10-Q (accession 0001847367-25-000028): "With the favorable results in our Phase 2 clinical trial in PsO, we have initiated our Phase 3 ONWARD clinical program, which consists of two parallel Phase 3 clinical trials of ESK-001 in this indication and for which we expect to report topline results early in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000184736725000028/alms-20250331x10q.htm
- SEC Form 10-K (accession 0001847367-25-000012): "With the favorable results in our Phase 2 clinical trial in PsO, we have initiated our Phase 3 ONWARD clinical program, which consists of two parallel Phase 3 clinical trials of ESK-001 in this indication and for which we expect to report topline results in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000184736725000012/tmb-20241231x10k.htm
- SEC Form 10-Q (accession 0001847367-24-000005): "With the favorable results in our Phase 2 clinical trial in PsO, we have initiated our Phase 3 ONWARD clinical program, which consists of two parallel Phase 3 clinical trials of ESK-001 in this indication and for which we expect to report topline results in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000184736724000005/tmb-20240930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-021990): "- Phase 3 ONWARD program ongoing with topline data expected in Q1 2026" https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-010169): "Alumis expects a Phase 2 OLE 52-week data update in PsO in 2025, Phase 3 topline data for PsO in the first half of 2026 and Phase 2b topline data for SLE in 2026." https://www.sec.gov/Archives/edgar/data/1847367/000110465925010169/tm254989d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-021990): ""We continue to progress and enroll patients with moderate-to-severe psoriasis in the pivotal Phase 3 ONWARD studies and expect to report topline data in the first quarter of 2026."" https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-25-000039): ""With patient enrollment now complete in the pivotal Phase 3 ONWARD program for plaque psoriasis and the Phase 2b LUMUS trial in SLE, Alumis has achieved key clinical milestones for envudeucitinib, or "envu" (formerly known as ESK-001), and we look forward to topline data from ONWARD expected in early Q1 2026, and LUMUS topline data expected to follow in Q3 2026," said Martin Babler, President and Chief Executive Officer of Alumis." https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-03-19, last confirmed 2026-03-19.
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000004): "o Alumis will provide an update of the TYK2 franchise strategy for both programs in the second quarter of 2026, including a timing update for commencing A-005's Phase 2 trial." https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm

### June 23, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: SLE.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05966480 (Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-23 (ACTUAL); Lead Sponsor Alumis Inc." https://clinicaltrials.gov/study/NCT05966480

### Q3 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: systemic lupus erythematosus, with topline data.
- First seen 2025-08-13, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000016): "- Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026 -" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000016): "Alumis anticipates potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE in the third quarter of 2026, a milestone with the potential to open the Type I interferon disease pathway for the TYK2 franchise." https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000009): "- Potentially pivotal Phase 2b topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 -" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000009/alms-20260514xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-036386): "Envudeucitinib is also being evaluated in LUMUS, a potentially pivotal Phase 2b clinical trial in patients with systemic lupus erythematosus, with topline data expected in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000004): "- Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 -" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-001073): "Topline data from the LUMUS Phase 2b trial of envudeucitinib in systemic lupus erythematosus (SLE) are expected to be announced in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-001073): "Envudeucitinib is also being evaluated in LUMUS, a potentially pivotal Phase 2b clinical trial in patients with systemic lupus erythematosus, with topline data expected in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-25-000039): "-Completed enrollment in Phase 2b LUMUS clinical trial for envudeucitinib in systemic lupus erythematosus (SLE); topline readout expected in Q3 2026-" https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-036386): "All statements, other than statements of historical facts, including without limitation those regarding Alumis' plans to submit an NDA in the second half of 2026, the potential for envudeucitinib to play a leading role in the treatment of patients with moderate-to-severe plaque psoriasis, the timing of Alumis' topline readout in its LUMUS Phase 2b program and statements regarding" https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-093353): "Phase 3 long-term extension study in moderate-to-severe plaque psoriasis, and LUMUS, a potentially pivotal Phase 2b trial in systemic lupus erythematosus, with topline data anticipated in Q3 2026." https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-078507): "Phase 2b LUMUS SLE topline results expected Q3 2026" https://www.sec.gov/Archives/edgar/data/1847367/000110465926078507/tm2619143d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000004): "We look forward to our clinical topline readout for our potentially pivotal LUMUS Phase 2b trial in SLE, anticipated in the third quarter of this year."" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm

### Q4 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: with moderate-to-severe plaque psoriasis, the timing of Alumis' topline readout.
- First seen 2026-01-06, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000022): "- Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 -" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000022): "Alumis remains on track to submit its New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000022): "All statements contained in this press release other than statements of historical fact are forward-looking statements, including without limitation statements regarding: Alumis' plans and anticipated timing for submitting an NDA for envudeucitinib in the fourth quarter of 2026" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-104145): "Alumis has reported positive results from its Phase 3 ONWARD program of envudeucitinib in moderate-to-severe plaque psoriasis and plans to file an NDA in moderate-to-severe plaque psoriasis in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000016): "- Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 -" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000016): "Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in PsO in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-093353): "All statements, other than statements of historical facts, including without limitation those regarding Alumis' plans to submit an NDA in the fourth quarter of 2026, the potential for envudeucitinib to be a leading therapy for patients with moderate-to-severe plaque psoriasis, the timing of" https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000009): "- Data continue to underscore envudeucitinib's potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track -" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000009/alms-20260514xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-036386): "All statements, other than statements of historical facts, including without limitation those regarding Alumis' plans to submit an NDA in the second half of 2026, the potential for envudeucitinib to play a leading role in the treatment of patients with moderate-to-severe plaque psoriasis, the timing of Alumis' topline readout in its LUMUS Phase 2b program and statements regarding" https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000004): "- Plan to submit NDA for envudeucitinib in PsO in 2H 2026 -" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm
- SEC Form 10-Q (accession 0001847367-26-000018): "the timing or likelihood of regulatory filings or other actions and related regulatory authority responses, including our plans to submit a New Drug Application ("NDA") for envudeucitinib ("envu"), formerly known as ESK-001, in moderate-to-severe plaque psoriasis ("PsO") in the fourth quarter of 2026;" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000018/alms-20260630x10q.htm
- SEC Form 10-Q (accession 0001847367-26-000024): "the timing or likelihood of regulatory filings or other actions and related regulatory authority responses, including our plans to submit a New Drug Application ("NDA") for envudeucitinib ("envu"), formerly known as ESK-001, in moderate-to-severe plaque psoriasis ("PsO") by the end of 2026;" https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-05-14, last confirmed 2026-05-14.
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000009): "Babler added, "We remain on track for our NDA submission in the fourth quarter of this year, as well as the potentially pivotal LUMUS Phase 2b topline readout in SLE in the third quarter." https://www.sec.gov/Archives/edgar/data/1847367/000184736726000009/alms-20260514xex99d1.htm

### 1H 2027: trial start

- Status: scheduled. Date confidence: half. Stage: 2. Indication: Parkinson's disease.
- First seen 2026-08-13, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0001847367-26-000016): "Alumis plans to initiate a Phase 2 biomarker trial for A-005, its central nervous system penetrant TYK2 inhibitor, in patients with Parkinson's disease, in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05739435 (Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-01 (ESTIMATED); Lead Sponsor Alumis Inc." https://clinicaltrials.gov/study/NCT05739435

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05739435 (Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-01 (ESTIMATED); Lead Sponsor Alumis Inc." https://clinicaltrials.gov/study/NCT05739435

## Same indication

- [Otezla (apremilast)](https://sec-api.dev/pdufa/apremilast) (AMGN)
- [ARV-102](https://sec-api.dev/pdufa/arv-102) (ARVN)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Open-label envudeucitinib](https://sec-api.dev/pdufa/open-label-envudeucitinib) (ALMS)
- [ORKA-001](https://sec-api.dev/pdufa/orka-001) (ORKA)
- [Orka-001 induction dose](https://sec-api.dev/pdufa/orka-001-induction-dose) (ORKA)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)
- [Piclidenoson](https://sec-api.dev/pdufa/piclidenoson) (CANF)
- [Rexaceract](https://sec-api.dev/pdufa/rexaceract) (GANX)
- [TAK-279](https://sec-api.dev/pdufa/tak-279) (TAK)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [Juvmo (tavapadon)](https://sec-api.dev/pdufa/tavapadon) (ABBV)
- [WEZLANA® (ustekinumab)](https://sec-api.dev/pdufa/ustekinumab) (JNJ)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zl-1102 1% w/w gel bid for 16 weeks](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) (ZLAB)

Calendar months: [December 2027](https://sec-api.dev/fda-calendar/2027-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/envudeucitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Envudeucitinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/envudeucitinib

```bibtex
@misc{secapidev_pdufa_envudeucitinib_20261116,
  title        = {Envudeucitinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/envudeucitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_envudeucitinib_20261116","title":"Envudeucitinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/envudeucitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
